GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
The Pharma Data
JUNE 2, 2022
A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialisation capabilities to make this exciting new technology available to those in need.”
52 
Let's personalize your content